Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

Abstract The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lorena Vigón, Sonia Vázquez-Morón, Juan Berenguer, Juan González-García, Ma Ángeles Jiménez-Sousa, Josep M. Guardiola, Manuel Crespo, Ignacio de Los Santos, Miguel A. Von Wichmann, Ana Carrero, María Belén Yélamos, Julián Gómez, Salvador Resino, Isidoro Martínez, The GESIDA 3603b Cohort Study Group
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/95a0dae2b93d4d7bbc800030ea9bfa0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:95a0dae2b93d4d7bbc800030ea9bfa0a
record_format	dspace
spelling	oai:doaj.org-article:95a0dae2b93d4d7bbc800030ea9bfa0a2021-12-02T15:10:02ZRapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR10.1038/s41598-019-48592-52045-2322https://doaj.org/article/95a0dae2b93d4d7bbc800030ea9bfa0a2019-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-019-48592-5https://doaj.org/toc/2045-2322Abstract The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.Lorena VigónSonia Vázquez-MorónJuan BerenguerJuan González-GarcíaMa Ángeles Jiménez-SousaJosep M. GuardiolaManuel CrespoIgnacio de Los SantosMiguel A. Von WichmannAna CarreroMaría Belén YélamosJulián GómezSalvador ResinoIsidoro MartínezThe GESIDA 3603b Cohort Study GroupNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lorena Vigón Sonia Vázquez-Morón Juan Berenguer Juan González-García Ma Ángeles Jiménez-Sousa Josep M. Guardiola Manuel Crespo Ignacio de Los Santos Miguel A. Von Wichmann Ana Carrero María Belén Yélamos Julián Gómez Salvador Resino Isidoro Martínez The GESIDA 3603b Cohort Study Group Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
description	Abstract The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
format	article
author	Lorena Vigón Sonia Vázquez-Morón Juan Berenguer Juan González-García Ma Ángeles Jiménez-Sousa Josep M. Guardiola Manuel Crespo Ignacio de Los Santos Miguel A. Von Wichmann Ana Carrero María Belén Yélamos Julián Gómez Salvador Resino Isidoro Martínez The GESIDA 3603b Cohort Study Group
author_facet	Lorena Vigón Sonia Vázquez-Morón Juan Berenguer Juan González-García Ma Ángeles Jiménez-Sousa Josep M. Guardiola Manuel Crespo Ignacio de Los Santos Miguel A. Von Wichmann Ana Carrero María Belén Yélamos Julián Gómez Salvador Resino Isidoro Martínez The GESIDA 3603b Cohort Study Group
author_sort	Lorena Vigón
title	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
title_short	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
title_full	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
title_fullStr	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
title_full_unstemmed	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
title_sort	rapid decrease in titer and breadth of neutralizing anti-hcv antibodies in hiv/hcv-coinfected patients who achieved svr
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/95a0dae2b93d4d7bbc800030ea9bfa0a
work_keys_str_mv	AT lorenavigon rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT soniavazquezmoron rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT juanberenguer rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT juangonzalezgarcia rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT maangelesjimenezsousa rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT josepmguardiola rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT manuelcrespo rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT ignaciodelossantos rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT miguelavonwichmann rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT anacarrero rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT mariabelenyelamos rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT juliangomez rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT salvadorresino rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT isidoromartinez rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr AT thegesida3603bcohortstudygroup rapiddecreaseintiterandbreadthofneutralizingantihcvantibodiesinhivhcvcoinfectedpatientswhoachievedsvr
_version_	1718387767259430912

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

Ejemplares similares